

VX18-445-110: A Phase 3, Open-label Study Evaluating the Long term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Status: Completed

Eligibility Criteria

Sex: All

Age: 12 Years and over

This study is NOT accepting healthy volunteers

Key

Inclusion Criteria:

- Completed study drug treatment in parent study (VX18-445-104); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study Key

Exclusion Criteria:

- History of study drug intolerance in parent study Other protocol defined Inclusion/Exclusion criteria may apply

Conditions & Interventions

Interventions:

Drug: ELX/TEZ/IVA, Drug: IVA

Conditions:

Cystic Fibrosis

More Information

Description: This is an open-label study for patients rolling over from VX18-445-104. This study will evaluate the long-term safety and efficacy of VX-445 combination therapy in subjects with CF.

Contact(s): Mary Bailey - mpbailey@umn.edu

Principal Investigator: Joanne Billings

Phase: Phase 3

IRB Number: STUDY00006925

System ID: NCT04058366

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.